Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donafenib in previously treated metastatic gastric cancer
NCT02489214Phase 2Terminated
- Sponsor
- Zelgen
- Start
- May 2016
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of donafenib in gastric cancer (GC), sponsored by Zelgen. Started May 2016; status: terminated.
02
Drugs
donafenib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT02489214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02489214.